Technical Analysis for PER - Percheron Therapeutics Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -5.13% | |
| Narrow Range Bar | Range Contraction | -5.13% | |
| Oversold Stochastic | Weakness | -5.13% | |
| Fell Below 20 DMA | Bearish | -5.13% | |
| 180 Bearish Setup | Bearish Swing Setup | -5.13% |
| Alert | Time |
|---|---|
| Down 5% | about 7 hours ago |
| Down 3% | about 7 hours ago |
| Fell Below Lower Bollinger Band | about 7 hours ago |
| Fell Below Previous Day's Low | about 12 hours ago |
| Down 2% | about 12 hours ago |
Get a Trading Sidekick!
Percheron Therapeutics Limited Description
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Toorak, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Diseases Pharmaceuticals Asthma Multiple Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.14 |
| 52 Week Low | 0.052 |
| Average Volume | 3,195,066 |
| 200-Day Moving Average | 0.083 |
| 50-Day Moving Average | 0.092 |
| 20-Day Moving Average | 0.080 |
| 10-Day Moving Average | 0.080 |
| Average True Range | 0.005 |
| RSI (14) | 38.65 |
| ADX | 17.77 |
| +DI | 21.760 |
| -DI | 32.000 |
| Chandelier Exit (Long, 3 ATRs) | 0.075 |
| Chandelier Exit (Short, 3 ATRs) | 0.088 |
| Upper Bollinger Bands | 0.085 |
| Lower Bollinger Band | 0.075 |
| Percent B (%b) | -0.1 |
| BandWidth | 12.500 |
| MACD Line | -0.004 |
| MACD Signal Line | -0.004 |
| MACD Histogram | -0.0001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.080 | ||||
| Resistance 3 (R3) | 0.081 | 0.079 | 0.079 | ||
| Resistance 2 (R2) | 0.079 | 0.078 | 0.079 | 0.079 | |
| Resistance 1 (R1) | 0.077 | 0.077 | 0.076 | 0.076 | 0.078 |
| Pivot Point | 0.075 | 0.075 | 0.075 | 0.075 | 0.075 |
| Support 1 (S1) | 0.073 | 0.074 | 0.072 | 0.072 | 0.070 |
| Support 2 (S2) | 0.071 | 0.073 | 0.071 | 0.069 | |
| Support 3 (S3) | 0.069 | 0.071 | 0.069 | ||
| Support 4 (S4) | 0.068 |
